Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
1. GILD's Q4 EPS of $1.90 surpassed expectations by $0.20. 2. Sales rose 6% to $7.57 billion, driven by HIV segment growth. 3. HIV sales increased 16%, primarily from Biktarvy's growth. 4. Gilead raised its quarterly dividend by 2.6% to $0.79 per share. 5. Positive 2025 guidance anticipates higher EPS and sales than consensus.